Navigation

Psoriasis - infliximab

Infliximab for the treatment of psoriasis

Status: History
Expected date of issue: January 2008
Process: STA
Topic area:
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Prashanth Kandaswamy and Nicola Hay
Communications manager: Sarita Tamber
Project manager: Natalie Bemrose
Assessment Group / Evidence Review Group: Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 08 May 2007
1st appraisal committee meeting: 01 August 2007
2nd appraisal committee meeting 03 October 2007
Top


 

Consultees and commentators

Consultees Commentators (no right of appeal)

Manufacturers / Sponsors

  • Schering-Plough Ltd (infliximab)

Patient / Carer Groups

  • Arthritis and Musculoskeletal Alliance
  • Changing Faces
  • Psoriasis Association
  • Psoriatic Arthropathy Alliance
  • Skin Care Campaign
  • Specialised Healthcare Alliance

Professional Groups

  • British Association of Dermatologists
  • British Dermatological Nursing Group
  • British Skin Foundation
  • British Society for Rheumatology
  • Community Practitioners' & Health  Visitors Association
  • Primary Care Dermatology Society
  • Primary Care Rheumatology Society
  • RoyalCollegeof General Practitioners
  • Royal College of Nursing
  • Royal College of Paediatrics and Child Health
  • Royal Pharmaceutical Society

Others

  • BasildonPCT
  • Charnwood and North West Leicestershire PCT
  • Department of Health
  • Welsh Assembly Government

General

  • Board of Community Health Councils in Wales
  • British National Formulary
  • Department of Health, Soc.
  • ial Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • National Public Health Service for Wales
  • NHS Confederation
  • NHS Purchasing and Supply Agency
  • NHS Quality Improvement Scotland
  • Scottish Medicines Consortium

Comparator Manufacturers

  • Serono (efalizumab)
  • Wyeth (etanercept, methotrexate)  
  • Novartis (ciclosporin)
  • Wockhardt UK ltd (methotrexate)
  • Mayne Pharma plc (methotrexate)
  • Bristol Myers Squibb (hydroxycarbamide)
  • Medac GmBH (hydroxycarbamide)

Evidence Review Groups

  • Southampton Health Technology Assessment Centre, University of Southampton
  • National Coordinating Centre for Health Technology Assessment

Associated Guideline Groups

  • None

Associated Public Health Groups

  • None

Research Groups

  • Cochrane Skin Group (Centre of Evidence-based Dermatology, University of Nottingham)
  • Skin Research Centre, University of Leeds
  • Skin Treatment and Research Trust (START)
  • MRC Clinical Trials Unit

Top


 

Project history

Date Update
5 September 2007 Project Manager Updated
25 August 2006 This topic was transferred to the Single technology appraisal (STA) process as part of the Institute's 12th wave work programme.
10 October 2006 Final scope and list of consultees and commentators published.
12 December 2006 At the request of the manufacturer, the timing of this STA has now been set to allow the inclusion of relevant utility data and healthcare resource utilisation data as part of the manufacturer's evidence submission for this already licensed technology.
20 March 2007 Communications manager updated.
Top


 

Key documents

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.